Y10S 424/831
Involving capsular polysaccharide of bacterium
Official title: involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate
Y10S424/831 (Involving capsular polysaccharide of bacterium) appears on 100 US grants and 53 published applications in this corpus.
Search patents in Y10S- Granted patents
- 100
- Published applications
- 53
- Assignees
- 61
- Inventors
- 142
- Latest grant
- 30 May 2023
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1980 | 4 | 0 |
| 1981 | 1 | 0 |
| 1982 | 0 | 0 |
| 1983 | 1 | 0 |
| 1984 | 3 | 0 |
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 6 | 0 |
| 1988 | 2 | 0 |
| 1989 | 2 | 0 |
| 1990 | 2 | 0 |
| 1991 | 4 | 0 |
| 1992 | 2 | 0 |
| 1993 | 2 | 0 |
| 1994 | 5 | 0 |
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 3 | 0 |
| 1998 | 2 | 0 |
| 1999 | 4 | 0 |
| 2000 | 1 | 0 |
| 2001 | 7 | 1 |
| 2002 | 4 | 6 |
| 2003 | 3 | 1 |
| 2004 | 2 | 3 |
| 2005 | 3 | 7 |
| 2006 | 3 | 4 |
| 2007 | 4 | 4 |
| 2008 | 1 | 1 |
| 2009 | 3 | 9 |
| 2010 | 2 | 7 |
| 2011 | 3 | 1 |
| 2012 | 0 | 3 |
| 2013 | 1 | 0 |
| 2014 | 6 | 0 |
| 2015 | 4 | 2 |
| 2016 | 2 | 1 |
| 2017 | 3 | 1 |
| 2018 | 0 | 1 |
| 2019 | 0 | 0 |
| 2020 | 2 | 0 |
| 2021 | 0 | 1 |
| 2022 | 0 | 0 |
| 2023 | 1 | 0 |
By publication year. Applications have been published since 2001.
Recent patents
- Bifidobacterium bifidum strain and strain-derived polysaccharide30 May 2023US 11,660,312 B2Institute for Basic Science
- Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides11 Aug 2020US 10,736,959 B2Glaxosmithkline Biologicals SA
- Capsular polysaccharide solubilisation and combination vaccines21 Jul 2020US 10,716,841 B2Glaxosmithkline Biologicals SA
- Conjugation of Staphylococcus aureus type 8 capsular polysaccharides12 Dec 2017US 9,839,686 B2Glaxosmithkline Biologicals SA
- Capsular polysaccharide solubilisation and combination vaccines10 Oct 2017US 9,782,466 B2Glaxosmithkline Biologicals SA
- Novel bifidobacterium bifidum strain and strain-derived polysaccharide18 Mar 2021US 2021/0077521 A1Institute for Basic Science
- Conjugation of staphylococcus aureus type 5 and type 8 capsular polysaccharides7 Jun 2018US 2018/0153983 A1Glaxosmithkline Biologicals SA
- Capsular polysaccharide solubilisation and combination vaccines16 Feb 2017US 2017/0043004 A1Glaxosmithkline Biologicals SA
- Conjugation of staphylococcus aureus type 8 capsular polysaccharides25 Feb 2016US 2016/0051667 A1Novartis AG
- Meningococcal And Pneumococcal Conjugate Vaccine And Method Of Using Same2 Jul 2015US 2015/0182613 A1Howard University
Most cited
By later US patents
- Immunogenic conjugates154US 4,673,574 A1987
- Oligosaccharide conjugate vaccines99US 5,153,312 AAmerican Cyanamid Company · 1992
- Immunogenic conjugates93US 4,902,506 AUniversity of Rochester · 1990
- Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency89US 4,695,624 AMerck & Co., Inc. · 1987
- Oligosaccharide conjugate vaccines75US 5,306,492 AAmerican Cyanamid Company · 1994